Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

NCT04438096 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipidemia

Interventions

DRUG: 100 mg
DRUG: 200 mg
DRUG: 300 mg
DRUG: Placebo

Sponsor

CVI Pharmaceuticals